PeptiDream's Development and Commercialization Deal with Takeda Deal Date: Jul. 26, 2021 Deal Value: $3.5 B PeptiDream granted Takeda exclusive, worldwide rights to develop and commercialize peptide-drug conjugates (PDCs) for CNS indications in chronic neurodegenerative diseases. This is a major expansion of an original 2020 partnership between PeptiDream and Takeda (the collaboration is to develop PDCs for neuromuscular disease, peptides developed by PeptiDream and JCR for specific drug payloads selected by Takeda). This new collaboration expands the TfR1 binding peptide ligands for CNS targets associated with neurodegeneration, allowing Takeda to conjugate the peptides with therapeutic cargoes optimized to cross the blood-brain barrier (BBB). In addition, PeptiDream may receive up to a total of $3.5B (JPY 390.3B) in up front and milestone payments, plus royalties. 3.